Further studies concerning glucagon-induced hypocholesterolemia.
Some of the possible mechanisms responsible for the hypocholesterolemic effect of glucagon were investigated. Glucagon was found to inhibit the intestinal absorption of cholesterol. In addition, it was found to either hasten the rate of egress of lipoprotein cholesterol from the blood into the liver or to retard the rate of re-entry of cholesterol from the liver into the blood. The data do not distinguish between these two possibilities, which indeed may occur simultaneously.
D000085:Acetates / Q000378:metabolism; D000818:Animals; D000924:Anticholesteremic Agents; D001647:Bile Acids and Salts / Q000378:metabolism; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D002914:Chylomicrons / Q000378:metabolism; D005934:Glucagon / Q000494:pharmacology*; D007279:Injections, Subcutaneous; D007408:Intestinal Absorption / Q000187:drug effects; D008074:Lipoproteins / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008657:Metabolic Clearance Rate / Q000187:drug effects; D051381:Rats; D013997:Time Factors; D014316:Tritium
D000085:Acetates; D000924:Anticholesteremic Agents; D001647:Bile Acids and Salts; D002914:Chylomicrons; D008074:Lipoproteins; D014316:Tritium; D005934:Glucagon; D002784:Cholesterol